Crescita Therapeutics Inc Cash Flow Conversion Efficiency

Latest as of December 2025: 0.027x

Crescita Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Crescita Therapeutics Inc (CTX) has a cash flow conversion efficiency ratio of 0.027x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$416.00K ≈ $300.93K USD) by net assets (CA$15.58 Million ≈ $11.27 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Crescita Therapeutics Inc (2014–2025)

Cash flow conversion efficiency of Crescita Therapeutics Inc from 2014 to 2025. This chart illustrates how Crescita Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View CTX stock price and chart for real-time trading data and today's change.

Crescita Therapeutics Inc Cash Flow Conversion Ratio Explained

Crescita Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Crescita Therapeutics Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Crescita Therapeutics Inc ranked by their cash flow conversion efficiency. Also see CTX market cap for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Perfect Moment Ltd. NYSE MKT:PMNT	2.134x
HUHUTECH International Group Inc. Ordinary Shares NASDAQ:HUHU	0.065x
RomReal Limited OL:ROM	-0.020x
SL Private Equity LSE:SLPE	-0.001x
Neungyule Education Inc KQ:053290	0.065x
K-Tig Ltd AU:KTG	0.748x
TPC Power Holding Public Company Limited BK:TPCH	0.062x
Toyo Ventures Holdings Bhd KLSE:7173	0.099x

Annual Cash Flow Conversion Efficiency for Crescita Therapeutics Inc (2014–2025)

The table below shows the annual cash flow conversion efficiency of Crescita Therapeutics Inc from 2014 to 2025. Review Crescita Therapeutics Inc (CTX) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CA$15.58 Million ≈ $11.27 Million	CA$1.07 Million ≈ $776.19K	0.069x	-59.98%
2024-12-31	CA$15.83 Million ≈ $11.45 Million	CA$2.73 Million ≈ $1.97 Million	0.172x	+56.08%
2023-12-31	CA$18.82 Million ≈ $13.62 Million	CA$2.08 Million ≈ $1.50 Million	0.110x	+328.12%
2022-12-31	CA$21.10 Million ≈ $15.26 Million	CA$-1.02 Million ≈ $-737.85K	-0.048x	+37.86%
2021-12-31	CA$20.53 Million ≈ $14.85 Million	CA$-1.60 Million ≈ $-1.16 Million	-0.078x	-129.32%
2020-12-31	CA$21.13 Million ≈ $15.29 Million	CA$5.61 Million ≈ $4.06 Million	0.265x	+5.57%
2019-12-31	CA$21.11 Million ≈ $15.27 Million	CA$5.31 Million ≈ $3.84 Million	0.251x	+423.27%
2018-12-31	CA$19.01 Million ≈ $13.75 Million	CA$-1.48 Million ≈ $-1.07 Million	-0.078x	+86.23%
2017-12-31	CA$13.11 Million ≈ $9.48 Million	CA$-7.40 Million ≈ $-5.35 Million	-0.565x	+18.50%
2016-12-31	CA$26.81 Million ≈ $19.39 Million	CA$-18.58 Million ≈ $-13.44 Million	-0.693x	-116.76%
2015-12-31	CA$-3.37 Million ≈ $-2.43 Million	CA$-13.92 Million ≈ $-10.07 Million	4.135x	-6.57%
2014-12-31	CA$-2.10 Million ≈ $-1.52 Million	CA$-9.30 Million ≈ $-6.73 Million	4.426x	--

About Crescita Therapeutics Inc

TO:CTX Canada Drug Manufacturers - Specialty & Generic

Market Cap

$10.64 Million

CA$14.71 Million CAD

Market Cap Rank

#26773 Global

#1091 in Canada

Share Price

CA$0.79

Change (1 day)

+0.00%

52-Week Range

CA$0.42 - CA$0.79

All Time High

CA$1.82